Jim Lee

Company: Incyte

Job title: Head Immunology & Inflammation

Seminars:

The Story of Ruxolitinib: The First Approved Topical JAK Inhibitor for Atopic Dermatitis 10:15 am

The story from discovery to clinical development for a moderate to severe inflammatory skin indication Inspecting the JAK/STAT pathways critical to Incyte’s JAK inhibitor portfolio Reviewing the commercialization and market strategy of a ‘twice daily’ applied topical creamRead more

day: Day One